FDA Approves Eli Lilly’s Zepbound for Sleep Apnoea in Obese Adults

The US Food and Drug Administration (FDA) has approved Eli Lilly’s Zepbound (tirzepatide) as the first prescription medication for adults with moderate to severe obstructive sleep apnoea (OSA) and obesity. This approval marks a significant expansion in the use of Zepbound, initially sanctioned for obesity management, and it could reshape the approach to treating OSA, a condition that affects millions and is often associated with obesity.

Obstructive sleep apnoea is a prevalent sleep disorder characterized by repeated interruptions in breathing due to airways narrowing, often linked with obesity. Traditionally, the condition is managed using continuous positive airway pressure (CPAP) machines, which many patients struggle to tolerate.

The introduction of Zepbound as a treatment option offers a new pathway, particularly as studies showed patients losing significant weight when treated with tirzepatide. Moreover, the drug has already proven its efficacy in weight management, recording staggering sales for Eli Lilly alongside its diabetes counterpart, Mounjaro. This approval may further expand its market reach and is part of a broader trend of exploring weight loss drugs for diverse medical needs beyond obesity and diabetes.

The FDA’s approval of Zepbound for obstructive sleep apnoea signifies a groundbreaking advancement in treating the condition, offering new hope to many undiagnosed and untreated individuals. With its dual role in weight loss and sleep apnoea management, Zepbound is poised to gain significant traction, shaping the future of OSA treatment and enhancing the quality of life for affected individuals.

Contact Marcus for more details.